Aspire Biopharma
ASBP
17 hedge funds and large institutions have $18.2M invested in Aspire Biopharma in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
21% more funds holding
Funds holding: 14 → 17 (+3)
7% more capital invested
Capital invested by funds: $17M → $18.2M (+$1.14M)
0.01% more ownership
Funds ownership: 0% → 0.02% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$1.38M |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$890K |
| 3 |
FTCM
Fir Tree Capital Management
New York
|
+$851K |
| 4 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$541K |
| 5 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$387K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
-$1.59M |
| 2 |
SIM
Sandia Investment Management
Boston,
Massachusetts
|
-$1.56M |
| 3 |
CS
Clear Street
New York
|
-$516K |
| 4 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
-$516K |
| 5 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
-$180K |
ASBP Hedge Fund Activity: Q3 2023 in Review
17 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q3 2023, worth a combined $18.2M — up 6.7% from $17M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ASBP positions and 3 closed out — a net gain of 3 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was First Trust Capital Management, opening a new position worth an estimated $1.38M. The largest seller was Kepos Capital, exiting entirely with an estimated $1.59M sold.
- 17 institutional investors held Aspire Biopharma (ASBP) as of Q3 2023, up from 14 in Q2 2023.
- Funds reported $18.2M of Aspire Biopharma stock for Q3 2023, up 6.7% quarter-over-quarter.
- 6 funds opened new Aspire Biopharma positions in Q3 2023 and 3 closed out, a net change of +3 holders.
- The largest Aspire Biopharma buyer in Q3 2023 was First Trust Capital Management, an estimated $1.38M added.
- The largest Aspire Biopharma seller in Q3 2023 was Kepos Capital, an estimated $1.59M sold.
Based on aggregated 13F filings for Q3 2023.